Neurotriphic factor in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy

Massimiliano Mirabella, Anna Paola Batocchi, Giovanni Frisullo, Agata Katia Patanella, Cristina Sancricca, Viviana Nociti, Marcella Caggiula, Francesco Angelucci, Pietro Attilio Tonali

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Although interferon (IFN) beta is a widely used disease-modifying therapy in multiple sclerosis (MS), the mechanisms responsible for its effects are not fully understood. Some studies demonstrated that IFNbeta induces nerve growth factor (NGF) secretion by astrocytes and by brain endothelial cells. In this study, we determined the production of various neurotrophins (brain-derived neurotrophic factor, BDNF; NGF; glial cell line-derived neurotrophic factor; neurotrophin 3; neurotrophin 4) by peripheral blood mononuclear cells (PBMCs) in relapsing-remitting (RR) and secondary progressive (SP) MS patients during IFNbeta treatment. There were no main variations in neurotrophin production either among all MS patients globally considered or in the group of SPMS subjects. Instead, in the group of RRMS patients who did not present clinical exacerbation of disease up to the end of the study, we found a significant increase in BDNF production as from 6 months after starting therapy
Lingua originaleEnglish
pagine (da-a)77-82
Numero di pagine6
RivistaClinical Immunology
Stato di pubblicazionePubblicato - 2006

Keywords

  • interferon beta
  • multiple sclerosis
  • neurotrophic factors

Fingerprint

Entra nei temi di ricerca di 'Neurotriphic factor in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy'. Insieme formano una fingerprint unica.

Cita questo